Entire Brazilian city will be vaccinated against COVID-19 in giant experiment
Scientists will vaccinate all the adults in a single city to see whether a COVID-19 vaccine will reduce cases.
Get the world’s most fascinating discoveries delivered straight to your inbox.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered Daily
Daily Newsletter
Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.
Once a week
Life's Little Mysteries
Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.
Once a week
How It Works
Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more
Delivered daily
Space.com Newsletter
Breaking space news, the latest updates on rocket launches, skywatching events and more!
Once a month
Watch This Space
Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.
Once a week
Night Sky This Week
Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!
Join the club
Get full access to premium articles, exclusive features and a growing list of member rewards.
An entire Brazilian city will be vaccinated against COVID-19 in a giant experiment to test whether the vaccines reduce the spread of the virus.
The city of Serrana in the state of São Paulo is home to about 30,000 adults who will all be offered a COVID-19 vaccine within the next three months as part of a research study run by the Butantan Institute in Brazil.
Everyone in the city over the age of 18 (except for pregnant or breastfeeding women and those with serious illnesses) will be offered the CoronaVac vaccine, developed by Chinese company Sinovac, CNN reported. The aim of the study, known as "Project S," is to figure out whether the vaccine will reduce the spread of the virus.
Related: 20 of the worst epidemics and pandemics in history
While clinical trials have clearly shown that the Sinovac and other COVID-19 vaccines decrease the odds of developing symptomatic disease, data on whether vaccines could fully prevent infections (even asymptomatic ones) remain limited. Some of the earliest hints suggest at least some vaccines can prevent infections; a few weeks ago the University of Oxford published data indicating the Oxford-AstraZeneca vaccine could slow the spread of the virus, Live Science previously reported.
Of course, each vaccine will likely differ in its ability to prevent infection just as each has different efficacy at preventing mild or severe disease. Last month, the Butantan Institute announced that the CoronaVac vaccine had a 50.4% efficacy against symptomatic infection in Brazil, Live Science previously reported. Still, CoronaVac was 100% effective against death, according to The Associated Press (AP).
People will be allowed in and out of the city and participation in the study — which has already begun — won't be required but is expected to be high, the AP reported. Participants will be monitored for up to one year but the first results are expected to come in 12 weeks, according to the AP.
Get the world’s most fascinating discoveries delivered straight to your inbox.
"Based on what we are going to learn here, we will be able to tell the rest of the world what the actual effect of the vaccination against COVID-19 is," Ricardo Palacios, the director of clinical studies at the Butantan Institute, told CNN.
The announcement of this study prompted a rush to buy and rent property in Serrana, with people arriving in hopes of becoming residents to be able to participate in the study and get the vaccine, according to The Guardian. But officials said they would need a history of residence to register for the trial, according to the AP.
Brazil is one of the countries worst hit by the novel coronavirus, with nearly 10 million COVID-19 cases to date and more than 242,000 deaths, according to The Johns Hopkins Dashboard. Vaccine supplies are dwindling and have already run out in several cities, according to the AP. But a special batch of vaccines was designated for this study, and so there is no risk of it running out in Serrana.
Originally published on Live Science.

Yasemin is a staff writer at Live Science, covering health, neuroscience and biology. Her work has appeared in Scientific American, Science and the San Jose Mercury News. She has a bachelor's degree in biomedical engineering from the University of Connecticut and a graduate certificate in science communication from the University of California, Santa Cruz.
